ZVRA Zevra Therapeutics Inc Total Asset Value of Company

Zevra Therapeutics (ZVRA) invests in energy-efficient transportation and hazardous waste processing in compliance with ESG principles. The business model relies on third-party contractors for drug synthesis and packaging, retaining only development and promotion. This chart of total assets, which stands at 279.58, confirms growth driven by active sales of the Niemann-Pick disease treatment and the development of a promising product portfolio.

ZVRA (Zevra Therapeutics) Company Total Assets history from 04/28/2023 to 11/01/2026

Analytical breakdowns and data insights for company Kempharm (ZVRA)

- market value and analyst target forecast:

Stock Price zevra.com|ZVRA - Price Target Chart

- market capitalization data:

Market Valuation Zevra Corp|ZVRA - Enterprise Value

- issuer book value statistics:

Accounting Value of a Share Zevra Therapeutics|ZVRA - Book Capitalization|Market Capitalization to Book Value Ratio zevra.com|ZVRA - Aggregate Company Assets

- debt burden and liquidity indicators:

All Debt to Shareholders' Equity Ratio Zevra Therapeutics|ZVRA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Zevra Corp|ZVRA - Company Aggregate Debts|Debts to Book Capitalization Zevra Corp|ZVRA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Zevra Therapeutics|Immediate Liquidity Ratio zevra.com

- net income and valuation multiples indicators:

ZVRA - Net Profit

Fundamental valuation:Zevra Therapeutics

Manufactured products of Zevra Therapeutics

Total assets represent the aggregate value of all resources and ownership rights that form the material basis of the business. This metric is calculated inversely via return on assets (ROA), making it sensitive to operational efficiency. By analyzing the company's total resources, an investor can track the dynamics of capital accumulation. The Zevra Therapeutics (ZVRA) strategy of outsourcing production and trials minimizes the ownership of physical assets, thereby optimizing the structure of this balance sheet indicator.

Key competitors

jazzpharma.com (JAZZ) - Company Total Assets|Aggregate Company Assets Cytokinetics, Incorporated|PTC Therapeutics Inc - Total Asset Value of Company|Company Total Assets SRRK|CNTA (Centessa Corp) - Aggregate Asset Value|Company Total Assets DYN (Dyne Therapeutics, Inc.)|Company Total Assets edgewisetx.com EWTX|RAPP - Aggregate Company Assets|Aggregate Asset Value ALMS (Alumis Inc)|Contineum Pharma (CTNM) - Aggregate Company Assets|Cumulative Company Assets Larimar Corp|CAPR (Capricor Therapeutics Inc.) - Company Total Assets|Company Total Assets entradatx.com|Cumulative Company Assets PTHS (Channel Therapeutics Corp)|MNOV (medicinova.com) - Aggregate Asset Value|Aggregate Company Assets Serina SER|BTAI: Total Business Assets|ProMIS - Company Total Assets|Company Assets Apimeds Pharmaceuticals|AEON (aeonbiopharma.com) - Cumulative Company Assets|NLS Pharmaceutics (NLSP) - Company Total Assets|Aggregate Company Assets Bionomics Ltd.|HUGE: Aggregate Asset Value|Aggregate Company Assets Reata Pharmaceuticals (RETA)